XALACOM 50 MCG
LATANOPROST : 50 MCG TIMOLOL (TIMOLOL MALEATE) : 5 MG · DIN 02246619 · BGP PHARMA ULC
Health Canada status: MARKETED
What is XALACOM?
XALACOM 50 MCG contains LATANOPROST : 50 MCG TIMOLOL (TIMOLOL MALEATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02246619, held by BGP PHARMA ULC, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 24-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XALACOM used for?
Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension insufficiently responsive to beta-blockers, prostaglandins, or other IOP lowering agents.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02246619 |
|---|---|
| Brand name | XALACOM |
| Generic / active ingredient | LATANOPROST : 50 MCG TIMOLOL (TIMOLOL MALEATE) : 5 MG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 50 MCG |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01ED51 TIMOLOL, COMBINATIONS |
| AHFS class | 52:40.08 ; 52:40.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Jul-2023 |
| Original market date | 2002-10-24 00:00:00 |
How is it administered?
One drop in the affected eye(s) once daily. Not for initiating therapy. Systemic absorption reduced by nasolacrimal occlusion or closing eyelids for 2 minutes.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists section 11, but full text ends at section 8.2).
How is it supplied?
5 mL plastic ophthalmic dispenser bottle with dropper tip. Each bottle contains 2.5 mL of solution (approximately 80 drops).
Contraindications
Reactive airway disease (asthma, severe COPD); sinus bradycardia, sick sinus syndrome, AV block (2nd/3rd degree) without pacemaker, overt cardiac failure, cardiogenic shock; hypersensitivity.
Warnings and precautions
May cause permanent iris color change (increased brown pigment) and eyelash changes. Risk of systemic beta-blocker effects (cardiovascular/pulmonary). Caution in diabetes and myasthenia gravis.
What can be used instead?
Other Canadian products sharing ATC code S01ED51 TIMOLOL, COMBINATIONS. 21 of 50 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BRIMONIDINE-TIMOP | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02375311 |
| APO-DORZO-TIMOP | 5 MG | SOLUTION | APOTEX INC | MARKETED | DIN 02299615 |
| APO-TRAVOPROST-TIMOP PQ | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02415305 |
| AZARGA | 0.5 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02331624 |
| COMBIGAN | 0.2 % | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02248347 |
| COSOPT | 5 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02240113 |
| COSOPT PRESERVATIVE-FREE | 20 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02258692 |
| DORZOLAMIDE-TIMOLOL | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02522020 |
| DUOTRAV PQ | 0.5 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02278251 |
| JAMP BRIMONIDINE/TIMOLOL | 0.2 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02531704 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.